Expanded Carrier Screening Segment Leads Asia Pacific Cell and Gene Therapy Market Growth Based on Type
According to our new research study on “Asia Pacific Cell and Gene Therapy Market Forecast to 2031 – Regional Analysis – by Type, Service, Scale, Service Providers, Transfection Reagents, and End User,” the market is expected to grow from US$ 1,512.22 million in 2024 to US$ 8,988.18 million by 2031, registering a CAGR of 29.1% during 2025–2031. Major factors driving the Asia Pacific cell and gene therapy market expansion include the increasing prevalence of chronic and genetic diseases, supportive government initiatives, and the rapid popularity of outsourcing cell and gene therapy manufacturing.
Massive government investments, surging clinical trial activities, and increasing demand for advanced treatments targeting cancer, rare diseases, and genetic disorders propel the Asia Pacific cell and gene therapy market growth. The regulatory frameworks in these countries are improving, which, along with skilled talent pools and increasing manufacturing capacity, has made China, Japan, South Korea, India, Australia, and Singapore major hubs of the industry. The collaboration of global biopharma companies with regional CDMOs and research institutions is facilitating the pace of development and commercialization. Further, the region is being positioned as a significant source of advanced therapies due to ongoing advancements in viral vectors, cell processing, genome editing, and quality-control technologies.
Asia Pacific Cell and Gene Therapy Market, by Country, 2024 (%)
Asia Pacific Cell and Gene Therapy Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type [Cell Therapy (Allogeneic, Autologous, Viral Vectors), and Gene Therapy (Non-viral Vectors and Viral Vectors]), Service (Process Development, cGMP Manufacturing, Regulatory Services, and Bioassay Services), Scale (Pre-commercial or R&D Manufacturing and Commercial Scale Manufacturing), Service Providers (CDMOs and CMOs), Transfection Reagents (Polymer-based Transfection Reagents, Lipid-based Transfection Reagents, Viral Transduction Enhancers, and Other Transfection Reagents), End User (Contract Research Organizations, Pharmaceutical and Biopharmaceutical Companies, and Academic and Research Institutes), and Country
Asia Pacific Cell & Gene Therapy Market Forecast 2031
Download Free Sample
Source: The Insight Partners Analysis
Asia Pacific Cell and Gene Therapy Market Analysis Based on Segmental Evaluation:
By type, the market is bifurcated into cell therapy and gene therapy. Cell therapy accounted for the largest Asia Pacific cell and gene therapy market share in 2024. Cell therapy demand is driven by substantial research investment, expanding manufacturing capacity, and increasing adoption of regenerative and oncology treatments across the region.
The scope of the Asia Pacific cell and gene therapy market report encompasses an assessment of the market's performance in APAC. In terms of revenue, China dominated the Asia Pacific cell and gene therapy market in 2024.
The Asia Pacific cell and gene therapy market is segmented into Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, the Philippines, Vietnam, and the Rest of Asia Pacific. The rising prevalence of genetic disorders, cancers, and chronic diseases has created a strong need for advanced treatment modalities, motivating investment in cell and gene therapy (CGT) research and commercialization. Governments across countries such as China, Japan, South Korea, and Singapore are promoting biotechnology innovation through funding, fast-track regulatory pathways, and infrastructure development, accelerating clinical trial approvals and product launches. Cost-effective manufacturing capabilities and a large, diverse patient population make APAC an attractive hub for global pharmaceutical and biotech companies to conduct trials and expand market access. Increasing awareness of personalized medicine and improvements in healthcare infrastructure contribute to early adoption of advanced therapies. As academic institutions, research organizations, and hospitals collaborate more closely, translational research and technology transfer accelerate, boosting innovation.
According to GLOBOCAN 2022 data from the International Agency for Research on Cancer, China reported approximately 4,824,700 new cancer cases and 2,574,200 cancer deaths. The rising prevalence of cancer is underscoring the urgent need for targeted therapies, such as CAR-T cells. According to a report by China's Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) in June 2025, 115 clinical trials for CGT products were registered in 2024, representing a 42% increase from 2023. Companies such as Neukio are exploring allogeneic immune cell technologies, such as iPSC-CAR-NK cells, to address current limitations in cell therapy. These technological advancements enhance the efficiency and scalability of CGT manufacturing, driving the demand for specialized CDMO services. OBiO Technology, a leading CDMO in China specializing in cell and gene therapies, operates 15 GMP-certified vector production lines and 20 GMP cell therapy production lines.
WuXi AppTec (WuXi Advanced Therapies), Lonza, Samsung Biologics, AGC Biologics, GenScript Biotech, Syngene International Ltd, Novotech, SK pharmteco Inc, CMIC Group, Porton Pharma Solutions Ltd are among the leading companies profiled in the Asia Pacific cell and gene therapy market report.
n terms of service, the Asia Pacific cell and gene therapy market is segmented into process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held the largest Asia Pacific cell and gene therapy market share in 2024. Based on scale, the market is classified into pre-commercial/R&D manufacturing and commercial scale manufacturing. The pre-commercial/R&D manufacturing segment held the largest market share in 2024. Based on service providers, the Asia Pacific cell and gene therapy market is divided into CDMOs and CMOs. The CDMOs segment held the largest market share in 2024. In terms of transfection reagents, the market is categorized into polymer-based transfection reagents, lipid-based transfection reagents, viral transduction enhancers, and other transfection reagents. The lipid-based transfection reagents segment held the largest Asia Pacific cell and gene therapy market share in 2024. Based on end user, the market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held the largest market share in 2024. Based on geography, the market is categorized into Asia Pacific (China, India, South Korea, Japan, Singapore, Australia, Malaysia, Thailand, the Philippines, Vietnam, and the Rest of APAC).
Contact Us
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com